K

Kura Oncology
D

KURA

8.86000
USD
-0.08
(-0.89%)
Market Closed
Volume
39,709
EPS
-2
Div Yield
-
P/E
-4
Market Cap
688,986,825
OverviewSignalsIdeasNews
Related Instruments
    C
    COLM
    0.135
    (0.15%)
    87.325 USD
    G
    GPS
    0
    (0%)
    0.000000 USD
    LULU
    LULU
    2.29
    (0.60%)
    385.83 USD
    NKE
    NKE
    -0.080
    (-0.10%)
    76.670 USD
    P
    PVH
    1.030
    (0.96%)
    108.470 USD
    R
    RL
    1.180
    (0.51%)
    231.560 USD
    U
    UAA
    -0.00500
    (-0.06%)
    8.42500 USD
    U
    ULTA
    6.48
    (1.51%)
    435.35 USD
    V
    VFC
    -0.160
    (-0.73%)
    21.860 USD
    More
News

Title: Kura Oncology

Sector: Healthcare
Industry: Biotechnology
Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signaling pathways to drive the progression of various cancers. The company has a product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. Geographically operationof the group is carried through the United States.